Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123421 · ClinicalTrials.gov registry record
Develop and Validate Ultrasonic Device for Osteoporotic Fracture Risk Assessment
A clinical trial, sponsored by Artann Laboratories.
- Completed
- Registry status
- 113
- Enrollment target
NCT01123421: Completed study, sponsored by Artann Laboratories.
NCT01123421 is a clinical trial that has completed, run by Artann Laboratories. The registered enrollment target is 113 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01123421 has completed, sponsored by Artann Laboratories.
- COMPLETED
- Registry status
- 113 participants
- Enrollment target
Study Summary
Study to demonstrate that the Bone UltraSonic Scanner (BUSS) can aid in detection of osteoporosis and predict prevalent osteoporotic fractures. Measurements derived from the BUSS parameters will be able to discriminate between postmenopausal women with osteoporotic fractures when compared to matched controls without history of osteoporotic fracture.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-02 |
What the finished NCT01123421 record still lists
NCT01123421 is an observational study that tracks outcomes without assigning an intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01123421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01123421 about?
NCT01123421 is a clinical study titled "Develop and Validate Ultrasonic Device for Osteoporotic Fracture Risk Assessment". Study to demonstrate that the Bone UltraSonic Scanner (BUSS) can aid in detection of osteoporosis and predict prevalent osteoporotic fractures. Measurements derived from the BUSS parameters will be able to discriminate between postmenopausal women with osteoporotic fractures when compared to matched...
What is the current status of trial NCT01123421?
This trial is currently completed. The enrollment target is 113 participants. The study started on 2010-05. Estimated completion is 2012-02.
Who is sponsoring clinical trial NCT01123421?
This trial is sponsored by Artann Laboratories, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia